The lncRNA TRDN-AS (denoting “triadin antisense”) facilitates a balance between cardiac and skeletal isoforms of triadin, and it has been proposed for use in a candidate treatment strategy for heart failure (23). This evidence concerns the gene TRDN and heart failure.